These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25974285)

  • 21. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.
    Yu S; Wang S; Zou P; Chai G; Lin YW; Velkov T; Li J; Pan W; Zhou QT
    Int J Pharm; 2020 Feb; 575():118915. PubMed ID: 31816354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF; Ferrati S; Moraga-Espinoza DF; Smyth HDC
    J Pharm Sci; 2018 Aug; 107(8):2172-2178. PubMed ID: 29698726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
    Lababidi N; Ofosu Kissi E; Elgaher WAM; Sigal V; Haupenthal J; Schwarz BC; Hirsch AKH; Rades T; Schneider M
    J Control Release; 2019 Nov; 314():62-71. PubMed ID: 31654686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomonas aeruginosa pyocyanin production reduced by quorum-sensing inhibiting nanocarriers.
    Lu HD; Pearson E; Ristroph KD; Duncan GA; Ensign LM; Suk JS; Hanes J; Prud'homme RK
    Int J Pharm; 2018 Jun; 544(1):75-82. PubMed ID: 29608955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R; Parkins MD
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
    Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
    Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.
    Alipour M; Suntres ZE
    Ther Deliv; 2014 Apr; 5(4):409-27. PubMed ID: 24856168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study.
    Derbali RM; Aoun V; Moussa G; Frei G; Tehrani SF; Del'Orto JC; Hildgen P; Roullin VG; Chain JL
    Mol Pharm; 2019 May; 16(5):1906-1916. PubMed ID: 30900903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
    Pilcer G; Rosière R; Traina K; Sebti T; Vanderbist F; Amighi K
    J Pharm Sci; 2013 Jun; 102(6):1836-1846. PubMed ID: 23568616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Large Porous Particles for Sustained Release of a Decoy Oligonucelotide and Poly(ethylenimine): Potential for Combined Therapy of Chronic Pseudomonas aeruginosa Lung Infections.
    d'Angelo I; Perfetto B; Costabile G; Ambrosini V; Caputo P; Miro A; d'Emmanuele di Villa Bianca R; Sorrentino R; Donnarumma G; Quaglia F; Ungaro F
    Biomacromolecules; 2016 May; 17(5):1561-71. PubMed ID: 27002689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
    Salazar J; Müller RH; Möschwitzer JP
    Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections.
    Winstanley C; Fothergill JL
    FEMS Microbiol Lett; 2009 Jan; 290(1):1-9. PubMed ID: 19016870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections.
    Wagner S; Sommer R; Hinsberger S; Lu C; Hartmann RW; Empting M; Titz A
    J Med Chem; 2016 Jul; 59(13):5929-69. PubMed ID: 26804741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Chinese medicinal herbs on a rat model of chronic Pseudomonas aeruginosa lung infection.
    Song Z; Johansen HK; Moser C; Høiby N
    APMIS; 1996 May; 104(5):350-4. PubMed ID: 8703440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.